Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guanxinjing is a Traditional Chinese Medicine (TCM) formulation, typically administered as a capsule, used for the treatment of chronic stable angina pectoris. It is specifically indicated for patients presenting with Qi deficiency and blood stasis syndrome according to TCM principles. Developed and studied by institutions such as the Tianjin University of Traditional Chinese Medicine, it aims to improve clinical symptoms, cardiac function, and quality of life in patients with coronary heart disease. The formulation is a complex mixture of botanical extracts known in TCM for their ability to supplement Qi and invigorate blood flow. Clinical evaluations, including post-marketing studies, have focused on its efficacy in reducing the frequency of angina attacks and improving myocardial microcirculation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guanxinjing.